Victoria Hillerdal

Victoria Hillerdal is a Principal Scientist and RnD Immunology Lead at iCoat Medical AB since April 2023, with prior experience as a Senior Scientist at Sprint Bioscience and a Scientist II/Project Lead at Quell Therapeutics. Previously, Victoria held the position of Gene Engineering Scientist at GammaDelta Therapeutics and worked as a Postdoctoral Researcher at Uppsala Universitet. Victoria's research has focused on developing genetically engineered T cells for the treatment of cancer and autoimmune diseases, with a special emphasis on TCR directed against the prostate cancer-associated antigen TARP. Victoria earned a Master's degree in Molecular Biology from Uppsala University and a Bachelor's degree in Molecular Biology from Sofia University St. Kliment Ohridski.